Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Oncol., 13 August 2025

Sec. Head and Neck Cancer

Volume 15 - 2025 | https://doi.org/10.3389/fonc.2025.1672669

Correction: tRF-1:28-Val-CAC-2 promotes the development of nasopharyngeal cancer by targeting EPHB2

This article is a correction to:

  1. tRF-1:28-Val-CAC-2 promotes the development of nasopharyngeal cancer by targeting EPHB2

    1. Read original article
Hui Li,,&#x;Hui Li1,2,3†Xiaomin Wang,&#x;Xiaomin Wang2,3†Anchi Sun,&#x;Anchi Sun2,3†Weiwei LiuWeiwei Liu2Rongrong Lv,Rongrong Lv2,3Mingjie ZhangMingjie Zhang2Zhiwei XingZhiwei Xing2Shiyin Ma,*Shiyin Ma2,3*Yehai Liu*Yehai Liu1*Kai Zhang,,*Kai Zhang2,3,4*
  • 1Department of Otolaryngology-Head and Neck Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
  • 2Department of Otolaryngology-Head and Neck Surgery, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China
  • 3Anhui Engineering Technology Research Center of Biochemical Pharmaceutical, Bengbu, Anhui, China
  • 4Department of Stomatology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China

A Correction on
tRF-1:28-Val-CAC-2 promotes the development of nasopharyngeal cancer by targeting EPHB2

By Li H, Wang X, Sun A, Liu W, Lv R, Zhang M, Xing Z, Ma S, Liu Y and Zhang K (2025) Front. Oncol. 15:1564601. doi: 10.3389/fonc.2025.1564601

In the published article, there was an error in affiliation 1. Instead of “Anhui Medical University, Hefei, Anhui, China”, it should be “Department of Otolaryngology-Head and Neck Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China”.

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: tRF-1:28-Val-CAC-2, EPHB2, NPC, tsRNA, EMT

Citation: Li H, Wang X, Sun A, Liu W, Lv R, Zhang M, Xing Z, Ma S, Liu Y and Zhang K (2025) Correction: tRF-1:28-Val-CAC-2 promotes the development of nasopharyngeal cancer by targeting EPHB2. Front. Oncol. 15:1672669. doi: 10.3389/fonc.2025.1672669

Received: 24 July 2025; Accepted: 28 July 2025;
Published: 13 August 2025.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2025 Li, Wang, Sun, Liu, Lv, Zhang, Xing, Ma, Liu and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Kai Zhang, emsyOTc4OEAxNjMuY29t; Yehai Liu, bGl1eWVoYWlAYWhtdS5lZHUuY24=; Shiyin Ma, bWFzaGl5aW5lbnRAc2luYS5jb20=

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.